{'fraction_non_alphanumeric': 0.017152658662092625, 'fraction_numerical': 0.005145797598627788, 'mean_word_length': 4.84, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Negative Findings on Minocycline for ALS Prompts Reassessment of Study Designs

Chastened by the third major trial in a row to report negative findings for patients with amyotrophic lateral sclerosis (ALS), researchers say they are now moving more carefully before mounting the next major trial. The investigators concede that — spurred both by the desperation of patients and the allure of the superoxide dismutase (SOD1) mouse model of ALS — they may have been too hasty in the past to rush through the initial phase 1 and 2 studies; but they insist they have learned their lesson.